← Live radar Archive

📡 RADAR REPORT

Friday, 13 November 2026 · data as of 2026-11-13 20:22 UTC
ACTIVE TRIALS8,725
P3 READOUTS · 14D15
P3 READOUTS · 30D119
CHANGES · 7D0
LATE >6 MONTHS46%
Get the Radar Report by email — a weekly digest, free.

Phase 3 readouts due · next 14 days

15 trials with an exact primary-completion date in the next two weeks (119 in the next 30 days).
DateTrialSponsorAreaNvs. original plan
2026-11-13INAVO121Hoffmann-La Roche $ROG.SWOncology420-18.6 mo
2026-11-15ORCA-V2Achieve Life SciencesOther800—
2026-11-18POETYK SjS-1Bristol-Myers Squibb $BMYImmuno774+0.0 mo
2026-11-18Drugs-SNPsMedicine Invention Design, IncOncology600+30.0 mo
2026-11-20PembrolizumabMerck Sharp & Dohme LLC $MRKOncology990+17.1 mo
2026-11-21Cabergoline tabletsChangchun GeneScience Pharmaceutical Co., Ltd.Cardio-Met382+14.0 mo
2026-11-23Investigational varicella vaccineGlaxoSmithKline $GSKInfectious750+4.4 mo
2026-11-23dTpaGlaxoSmithKline $GSKInfectious102—
2026-11-24KarXTKaruna Therapeutics, Inc., a Bristol Myers Squibb companyNeuro406+0.8 mo
2026-11-24AvelumabEMD Serono Research & Development Institute, Inc. $MRK.DEOncology205+33.9 mo
2026-11-24177Lu-DOTATATE injectionHTA Co., Ltd.Other184+0.0 mo
2026-11-25ICP-332 TabletsBeijing InnoCare Pharma Tech Co., Ltd.Immuno552+0.0 mo
2026-11-25rilzabrutinibSanofi $SNYCardio-Met3-0.2 mo
2026-11-26RUBYTesaro, Inc.Oncology785+60.0 mo
2026-11-26MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd.Cardio-Met424+0.0 mo

Registry changes · last 7 days

Phase 3 / 2-3 trials whose ClinicalTrials.gov record changed (status, readout date, enrollment, sites), plus stops and results posted.

Change tracking started on 2026-11-13 — the first day-over-day changes appear after the next nightly run.

Delay Index

Across 5,352 active trials registered more than a year ago, 46% have moved their readout date by more than 6 months since first registration.

Most often late

SponsorTrials>6 mo late
Acerta Pharma BV1283%
Ionis Pharmaceuticals, Inc. $IONS1283%
Taiho Oncology, Inc.1070%
Allist Pharmaceuticals, Inc.1267%
Seagen, a wholly owned subsidiary of Pfizer $PFE1267%

Most on time

SponsorTrialsOn time ±1 mo
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. $1093.HK10100%
Qilu Pharmaceutical Co., Ltd.3388%
Ono Pharmaceutical Co., Ltd. $4528.T1385%
Biocad1283%
Shanghai JMT-Bio Inc.1283%

FDA this week

New NDA/BLA approvals and Class I drug recalls (last 7 days), and manufacturing (CGMP) or trial-conduct warning letters (last 14 days).
TypeWhatCompanyDate
✓ ApprovalOXDERYS (doxorubicin hydrochloride)AVYXA HOLDINGS2026-11-09
✓ ApprovalNDA221291BAYER HEALTHCARE $BAYN.DE2026-11-09
✓ ApprovalMULTIBIC (multibic)FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC2026-11-09
✉ Warning letterRequest for Records/CGMP/API/AdulteratedNanjing Hanxin Pharmaceutical Technology Co. Ltd.2026-11-03
✉ Warning letterCGMP/Finished Pharmaceuticals/AdulteratedUSV Private Limited2026-11-02

New Phase 3 trials · last 7 days

31 Phase 3 / 2-3 trials were first posted on ClinicalTrials.gov.
TrialSponsorAreaN
FrexalimabSanofi $SNYNeuro2500
AMBITION 3Novo Nordisk A/S $NVOCardio-Met1200
AMBITION4Novo Nordisk A/S $NVOCardio-Met1060
BerobenatidePfizer $PFECardio-Met900
RC118(Dose 1) plus RC148(Dose 1)RemeGen Co., Ltd.Oncology680
SYS6010CSPC Megalith Biopharmaceutical Co.,Ltd. $1093.HKOncology585
ABBV-722AbbVie $ABBVImmuno580
SHR-3167 InjectionJiangsu HengRui Medicine Co., Ltd. $600276.SSCardio-Met450
AMBITION 2Novo Nordisk A/S $NVOCardio-Met450
SYS6010 combined with EnlonstobartCSPC Megalith Biopharmaceutical Co.,Ltd. $1093.HKOncology424
QLS5132Qilu Pharmaceutical Co., Ltd.Oncology420
SUMMIT OLEUnited Therapeutics $UTHRCardio-Met400
TLX101-PxTelix Pharmaceuticals (Innovations) Pty LimitedOncology381
NP-101Novatek PharmaceuticalsOncology381
RC28-ERemeGen Co., Ltd.Cardio-Met350

Post text

Ready to paste on LinkedIn or X.
📡 TrialSonar Radar Report · 13 Nov 2026

⏱ 15 Phase 3 readouts due in the next 14 days (119 in 30):
• 2026-11-13 — INAVO121 (Hoffmann-La Roche $ROG.SW, Oncology)
• 2026-11-15 — ORCA-V2 (Achieve Life Sciences, Other)
• 2026-11-18 — POETYK SjS-1 (Bristol-Myers Squibb $BMY, Immuno)
• 2026-11-18 — Drugs-SNPs (Medicine Invention Design, Inc, Oncology)
• 2026-11-20 — Pembrolizumab (Merck Sharp & Dohme LLC $MRK, Oncology)

📉 Delay Index: 46% of active trials (registered >1 yr ago) have pushed their readout >6 months.
Most often late: Acerta Pharma BV 83%, Ionis Pharmaceuticals, Inc. 83%, Taiho Oncology, Inc. 70%

⚕ FDA: OXDERYS approved (AVYXA HOLDINGS); NDA221291 approved (BAYER HEALTHCARE); MULTIBIC approved (FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC); warning letter to Nanjing Hanxin Pharmaceutical Technology Co. Ltd.; warning letter to USV Private Limited

Full report & live map: /report/
Data: ClinicalTrials.gov, openFDA, fda.gov. Not investment advice.

Sources: ClinicalTrials.gov (U.S. NLM), openFDA and fda.gov warning letters. Primary completion dates are sponsor-reported and often estimates; readout = last primary-endpoint data collected, not results publication. For information only — not investment or medical advice. Disclaimer